Last reviewed · How we verify
Triamcinilone (kenalog)
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Rheumatoid arthritis and other inflammatory joint diseases, Allergic reactions and dermatitis, Asthma and respiratory inflammation.
At a glance
| Generic name | Triamcinilone (kenalog) |
|---|---|
| Sponsor | Henry Ford Health System |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Dermatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone acts as a glucocorticoid receptor agonist, entering cells and binding to intracellular glucocorticoid receptors. This leads to altered gene transcription, reducing production of pro-inflammatory cytokines and mediators. It suppresses T-cell activation, decreases antibody production, and stabilizes lysosomal membranes, resulting in broad anti-inflammatory and immunosuppressive effects.
Approved indications
- Rheumatoid arthritis and other inflammatory joint diseases
- Allergic reactions and dermatitis
- Asthma and respiratory inflammation
- Adrenocortical insufficiency
- Systemic lupus erythematosus and other autoimmune conditions
- Intra-articular injection for joint inflammation
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis (with chronic use)
- Immunosuppression/increased infection risk
- Cushingoid features (with chronic use)
- Insomnia
- Mood changes
- Gastrointestinal upset
Key clinical trials
- Effect of Epidural Steroid Injection on Bone Mineral Density in Postmenopausal Women (PHASE4)
- Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata (NA)
- Genicular Nerve Block in Juvenile Idiopathic Arthritis (PHASE4)
- Genicular Nerve Block in Rheuamtoid Arthritis (PHASE4)
- Impact of Sacroiliac Joint Injection on Bone Marrow Edema (NA)
- Ultrasound Guided Epidural Block in Axial SPA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |